|
Hepaconda® - A combination therapy for the treatment of Hepatitis C Virus
Hepatitis C Virus (HCV)
Hepatitis C Virus affects 3.1% of the world’s population and is currently the number one cause for liver transplantation in the United States. There are six primary genotypes of HCV and studies show that 70-75% of all infections are of the genotype one variety. Currently the most effective treatment for chronic HCV includes a combination of the drugs interferon alpha and ribavirin. This treatment is associated with a number of side effects and is only effective for 42 – 46% of patients, leaving a large portion with no effective therapy.
Hepaconda®
Hepaconda® is a combination of bezafibrate and chenodeoxycholic acid. It has been demonstrated in clinical trials that chenodeoxycholic acid, when used as a single compound, reduced Hepatitis C infection (HCV) and improved liver function in patients who have failed existing therapy. The combination of bezafibrate, which has been shown to eliminate HCV, with chenodeoxycholic acid, therefore appears to offer an advantage over current treatment.
USEFUL LINKS
Please note that Giaconda has no control over the information provided on these sites and is not responsible for the accuracy or otherwise of any information contained on them. If any of the links are no longer working, please notify us.
www.hepatitisaustralia.com
|
